News
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth company less than two months after it started.
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
Hims wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight-loss medicine, said ...
Daily Voice on MSN10h
Plainsboro-Based Wegovy Provider Ends Hims & Hers Deal Over Knockoff Weight-Loss Drug SalesNovo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...
Tesla shares rise sharply after the electric-vehicle company launched its highly anticipated robo-taxi service in Austin, ...
Meanwhile, Novo had agreed supply deals with Hims and several of its bigger rivals. The idea was to give their existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback